Stannsoporfin With Light Therapy for Newborn Babies With Jaundice

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

October 16, 2013

Primary Completion Date

March 22, 2016

Study Completion Date

March 22, 2016

Conditions
Jaundice, NeonatalHyperbilirubinemia, Neonatal
Interventions
PROCEDURE

Phototherapy

Phototherapy starts within 30 minutes before or after injection

DRUG

Stannsoporfin

Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)

DRUG

Placebo

Matching placebo administered by IM injection

Trial Locations (18)

11501

Winthrop University Hospital, Mineola

19102

Hahnemann University Hospital/St. Christopher's Hospital for Children, Philadelphia

22794

Stoney Brook Univ Hospital, Stony Brook

23298

Children's Hospital of Richmond at VCU, Richmond

27610

WakeMed Health and Hospitals, Raleigh

29425

Medical Univ of South Carolina, Charleston

32209

Univ Florida Hospital, Jacksonville

38163

University of Tennessee Health Science Center, Memphis

40202

Kosair Children's Hospital, Louisville

University of Louisville Hospital, Louisville

43606

Toledo Children's Hospital, Toledo

76104

JPS Health Network, Fort Worth

77555

Univ Texas Medical Branch, Galveston

89102

Univ Med Ctr of Southern Nevada, Las Vegas

92103

University of California San Diego Medical Center, San Diego

92324

Arrowhead Regional Medical Center, Colton

94145

University of CA, San Francisco, San Francisco

07103

Rutgers University Hospital, Newark

All Listed Sponsors
lead

InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

INDUSTRY

NCT01887327 - Stannsoporfin With Light Therapy for Newborn Babies With Jaundice | Biotech Hunter | Biotech Hunter